Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Sep 26.

Published in final edited form as: J Med Chem. 2013 Sep 4;56(18):7212–7221. doi: 10.1021/jm400474r

Cryptotanshinone directly binds to the SHP2 protein and functions as a mixed-type inhibitor. (A) Enzymatic kinetic analyses in the presence or absence of Cryptotanshinone (25 μM) were performed using GST-SHP2 PTP (1.0 μg) as the enzyme. V_max, K_cat, and K_m values in the absence or presence of this inhibitor were determined. Results shown in the table are mean±S.E.M. of three independent experiments. (B) Fluorescence titration of SHP2 was performed by increasing the concentrations of Cryptotanshinone while maintaining the SHP2 protein concentration (1.0 μg). The fluorescence is plotted against the log concentration in mol/L (Log [M]) for the compound. Experiments were repeated twice. Similar results were obtained in each. Data shown are mean±S.E.M. of triplicates from one representative experiment.

Cryptotanshinone directly binds to the SHP2 protein and functions as a mixed-type inhibitor. (A) Enzymatic kinetic analyses in the presence or absence of Cryptotanshinone (25 μM) were performed using GST-SHP2 PTP (1.0 μg) as the enzyme. V_max, K_cat, and K_m values in the absence or presence of this inhibitor were determined. Results shown in the table are mean±S.E.M. of three independent experiments. (B) Fluorescence titration of SHP2 was performed by increasing the concentrations of Cryptotanshinone while maintaining the SHP2 protein concentration (1.0 μg). The fluorescence is plotted against the log concentration in mol/L (Log [M]) for the compound. Experiments were repeated twice. Similar results were obtained in each. Data shown are mean±S.E.M. of triplicates from one representative experiment.